biostudies-literatureUnknown6(1)Obi Y<h4>Rationale & objective</h4>Patiromer is a potassium binder approved for the long-term management of hyperkalemia. Although patiromer use among patients with advanced chronic kidney disease (CKD) has been shown to reduce the discontinuation of renin-angiotensin-aldosterone system inhibition therapy, it remains unclear whether patiromer can improve clinical outcomes. The aim of this study was to examine the association of long-term patiromer use with clinical outcomes among hyperkalemic patients with CKD.<h4>Study design</h4>This was a longitudinal observational study.<h4>Setting & participants</h4>We evaluated a national cohort of 854,217 US Veterans who had at least 1 serum potassium measurement of ≥5.1 mEq/L and were treated at US Department of Veterans Affairs health care facilities bKidney medicine100757https://www.ebi.ac.uk/biostudies/studies/S-EPMC10772292biostudies-literatureLong-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort Study.PMC10772292Goedecke PDashputre AAObi YThomas FKovesdy CPfalseLong-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort Study.<h4>Rationale & objective</h4>Patiromer is a potassium binder approved for the long-term management of hyperkalemia. Although patiromer use among patients with advanced chronic kidney disease (CKD) has been shown to reduce the discontinuation of renin-angiotensin-aldosterone system inhibition therapy, it remains unclear whether patiromer can improve clinical outcomes. The aim of this study was to examine the association of long-term patiromer use with clinical outcomes among hyperkalemic patients with CKD.<h4>Study design</h4>This was a longitudinal observational study.<h4>Setting & participants</h4>We evaluated a national cohort of 854,217 US Veterans who had at least 1 serum potassium measurement of ≥5.1 mEq/L and were treated at US Department of Veterans Affairs health care facilities b2024-01-01T00:00:00Z2024 Jan2025-04-04T21:29:03.078Z2025-04-04T21:29:03.078ZS-EPMC107722923819243410.1016/j.xkme.2023.100757